Ireland
--:--IST
Recruiting Not applicable

Glucose Consumption During Deep Brain Stimulation With Functional [18F]FDG-Brain-PET in Obsessive-Compulsive Disorder

NCT05577598 · tracked via the Priya Life Science Austria tracker
Phase
Not applicable
Started
2022-04-01
Last updated
2025-06-13

Condition(s) studied

Obsessive-Compulsive DisorderPsychiatric Disorder

Investigational drug(s) / intervention(s)

Implantation of a DBS therapy system

Implantation of a DBS therapy system: The system is called "Reclaim DBS Therapy for OCD" und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.

Study summary

The purpose of this randomized, sham-controlled study is to evaluate the effectiveness of DBS therapy in individuals suffering from severe OCD and to investigate DBS treatment with functional \[18F\]FDG-Brain-PET.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * a score of 25 or higher on the Yale-Brown Obsessive Compulsive Scale * previous failure to respond to at least two medication trials with serotonin reuptake inhibitors at or, if tolerated, beyond the FDA maximum recommended dose for a minimum duration over at least ten weeks each. * at least one trial with tricyclic medication at or, if tolerated, beyond the FDA maximum recommended dose for a minimum duration over at least ten weeks each. * at least one trial of augmentation with antipsychotic medication, lithium, a benzodiazepine or buspirone * at least on trial of psychotherapy (cognitive behavioral therapy or comparable techniques) for at least 20 sessions * ability to provide written informed consent Exclusion Criteria: * any history of current or past psychotic disorder * a manic episode within the preceding three years * any current clinically significant medical or neurological disorder, that is a contraindication against DBS * any disease that could lead to an altered glucose reactivity (e.g. diabetes) * any clinically significant preoperative MRI abnormality or inability to undergo presurgical MRI * current or unstable remitted substance abuse or dependence except nicotine * pregnancy or high risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception * Any current severe personality disorder except comorbid anankastic personality disorder * Inability to follow the study protocol or adhere to operational requirements * Current and unstable suicidality

Primary outcome measure(s)

  • Change of metabolic rates of glucose response pattern — fPET measurements will take place in Week 4 and Week 5 of the trial.
    Change of metabolic rates of glucose response pattern

Trial sites (1)

FacilityCityRegionStatus
Medical University of Vienna, Department of Psychiatry and Psychotherapy Vienna State of Vienna Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05577598 on ClinicalTrials.gov ↗ ← All trials in Austria